Globenewswireยท2025-10-07 22:05Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Alto Neuroscience, Inc. (NYSE:ANRO) on behalf of long-term stockholders due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1][6]. Company Overview - Alto Neuroscience, Inc. is facing scrutiny following a class action complaint filed on July 21, 2025, concerning the period from February 2, 2024, to October 22, 2024 [1]. - The complaint alleges that the Offering Documents related to Alto's IPO were negligently prepared and that the effectiveness of ALTO-100 in treating Major Depressive Disorder (MDD) was overstated [6]. Financial Impact - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial for MDD, leading to a significant stock price drop of $10.17 per share, or 69.99%, closing at $4.36 per share on October 23, 2024 [6].